42 reports

(% market share) CHAPTER ##: PIPELINE DISRUPTORS: LYMPHOMA MARKET OPPORTUNITY Non-Hodgkin' s Lymphoma Table ##-##: Classification of Non-Hodgkin' s Lymphomas Hodgkin' s Lymphoma Figure ##-##: Global Incidence and Mortality of Lymphoma by Country, ##

  • Pathology
  • Respiratory Disease
  • Therapy
  • World
  • Market Size

Drugs For Respiratory Diseases P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A

  • Respiratory Disease
  • Market Size
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • GBI Research Report Guidance
  • RESPIRATORY DISORDERS THERAPEUTICS MARKET, GLOBAL, PIPELINE PRODUCTS, PRECLINICAL,

DURING CHILDHOOD, ASTHMA IS MORE COMMON IN MALES, WITH A MALE-TO-FEMALE RATIO OF ##:## UP TO PUBERTY, WHEN IT CHANGES TO ##:##.

  • Respiratory Disease
  • Market Size
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biologics, Inc.
  • 9 Appendix

Lung India; ##(##): ##-## AIHW (2016).

  • Respiratory Disease
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Novartis AG
  • Vectura Group plc
  • Asthma Therapeutics Market, Global, First-in-Class Molecular Targets in Pipeline Development, 2016
  • Asthma Therapeutics Market, Global, First-in-class Programs in Active Development Without Recorded Prior Deal

During childhood, asthma is more common in males, with a maleto-female ratio of ##:## up to puberty, when it changes to ##:##.

  • Respiratory Disease
  • Almirall, S.A.
  • AstraZeneca PLC
  • Genentech, Inc.
  • Novartis AG
  • Licensing and Collaboration

Lung cancer, breast cancer, lymphoma, and leukemia cause most malignant pleural effusions.

  • Pathology
  • Respiratory Disease
  • Therapy
  • United States
  • Amgen Inc.

Lung cancer, breast cancer, lymphoma, and leukemia cause most malignant pleural effusions.

  • Pathology
  • Respiratory Disease
  • Therapy
  • United States
  • Genelux Corporation

IN SUBJECTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA.

  • Blood Disease
  • Cell Therapy
  • Respiratory Disease
  • Therapy
  • Bristol-Myers Squibb Company
  • AB-8779 - DRUG PROFILE
  • ASTHMA - PIPELINE BY AB SCIENCE SA, H2 2018

LtxA has potent in vivo anti-lymphoma activity in mice.

  • Asthma
  • Respiratory Disease
  • United States
  • Company
  • AstraZeneca PLC

Poster presentation Nov ##, 2017: Regeneron to Share Clinical Progress of REGN1979 in B-Cell Lymphomas at the 2017 ASH Annual Meeting Regeneron Pharmaceuticals, Inc. announced that data from two studies, including Phase ## clinical trial of REGN1979, in patients with different forms

  • Immunotherapy
  • Pharmaceutical
  • Respiratory Disease
  • Therapy
  • Regeneron Pharmaceuticals, Inc.

Article ##.

  • Hospital
  • Respiratory Disease
  • Japan
  • United States
  • Kyowa Hakko Kirin Co., Ltd.
  • AB-8779 - DRUG PROFILE
  • RELIANCE LIFE SCIENCES PVT LTD

LtxA has potent in vivo anti-lymphoma activity in mice.

  • Asthma
  • Pharmaceutical
  • Research And Development
  • Respiratory Disease
  • AstraZeneca PLC
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Asthma
  • Respiratory Disease
  • World
  • Product Initiative
  • Merck & Co., Inc.
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Monoclonal Antibody
  • Respiratory Disease
  • Therapy
  • F. Hoffmann-La Roche Ltd.

Kymriah (tisagenlecleucel), first-in-class CAR-T therapy, received second FDA approval to treat appropriate relapsing/ refractory (r/ r) patients with large B-cell lymphoma.

  • Clinical Trial
  • Pulmonary Delivery
  • Respiratory Disease
  • United States
  • Novartis AG

The prominent features of this report are - ##.

  • Drug Development
  • Respiratory Disease
  • World
  • Product Initiative
  • Otsuka Pharmaceutical Co., Ltd.

CITY OF HOPE REPORTED THAT IT HAS EARNED ITS THIRD LYMPHOMA SPECIALIZED PROGRAMS OF RESEARCH EXCELLENCE (SPORE) GRANT FROM THE NATIONAL CANCER INSTITUTE (NCI), ONE OF JUST FOUR CURRENT NCISUPPORTED LYMPHOMA SPORES IN THE NATION.

  • Blood Disease
  • Cell Therapy
  • Respiratory Disease
  • Therapy
  • Bristol-Myers Squibb Company

The prominent features of this report are - ##.

  • OTC
  • Respiratory Disease
  • Therapy
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Clinical Trial
  • Pharmaceutical
  • Respiratory Disease
  • World
  • Product Initiative
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Allergy Drug
  • Drug Development
  • Pharmaceutical
  • Respiratory Disease
  • World

Hoffmann-La Roche Ltd ## ## ## ## ## ## Eli Lilly and Co ## ## ## ## ## ## E.

  • Clinical Trial
  • Pharmaceutical
  • Respiratory Disease
  • World
  • Product Initiative
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

## ## India ## ## ## ## ## ## ## ## Russia ## ## ## ## ## ## ## ## Brazil ## ## ## ## ## ## ## ## Mexico ## ## ## ## ## ## ## ## Indonesia ## ## ## ## ## ## ## ## Turkey Source: GlobalData' s Pharma Intelligence Center Clinical Tr

  • Anti-Infective
  • Clinical Trial
  • Pharmaceutical
  • Respiratory Disease
  • World

The prominent features of this report are - ##.

  • Asthma
  • Clinical Trial
  • Medical Biotechnology
  • Respiratory Disease
  • Novartis AG
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## Celgene Corp ## ## ## ## ## ## ## C.

  • Clinical Trial
  • Medical Biotechnology
  • Respiratory Disease
  • World
  • Product Initiative
  • RESOLYS BIO INC
  • CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) - PIPELINE BY RESPIRATORIUS AB, H2 2018

One study in T cell refractory lymphoma was accelerated to a Phase III randomized controlled trial validated by health authorities in the world.

  • Immunotherapy
  • Respiratory Disease
  • United States
  • Product Initiative
  • AstraZeneca PLC
  • ASTHMA - PIPELINE BY AB SCIENCE SA
  • ASTHMA - PIPELINE BY PROMMUNE INC

ABS has also developed KIT## for the treatment of aggressive mastocytosis, seminoma, and acute myeloid leukemia; and syk for rheumatoid arthritis, b-cell lymphoma, and others.

  • Pharmaceutical
  • Respiratory Disease
  • Company
  • Product Initiative
  • AstraZeneca PLC
  • RESOLYS BIO INC
  • CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) - PIPELINE BY AB SCIENCE SA, H1 2018

One study in T cell refractory lymphoma was accelerated to a Phase III randomized controlled trial validated by health authorities in the world.

  • Immunotherapy
  • Research And Development
  • Respiratory Disease
  • Therapy
  • AstraZeneca PLC

## ## Preclinical ## ## Discovery ## ## Unknown ## ## Total ## ## Products in Phase II/ III and I/ II are reflected under Phase III and Phase II, respectively Source: Global Markets Direct NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR IDIOPATHIC PULMONARY FIBROSIS, H## 2018 Stage of De

  • Pharmaceutical
  • Respiratory Disease
  • United States
  • Company
  • Product Initiative

IT IS ALSO UNDER DEVELOPMENT FOR THE TREATMENT OF REFRACTORY SOLID TUMORS AND LYMPHOMA.

  • Autoimmune Disease
  • Respiratory Disease
  • United States
  • Product Initiative
  • ProMetic Life Sciences Inc.

It is one of at least ## naturally occurring interleukins in the human body.

  • Asthma
  • Medical Biotechnology
  • Respiratory Disease
  • United States
  • Product Initiative